: FDA approves Reata’s rare disease drug amid questions about changes to the regulatory environment for neuroscience treatments

      Comments Off on : FDA approves Reata’s rare disease drug amid questions about changes to the regulatory environment for neuroscience treatments
: FDA approves Reata’s rare disease drug amid questions about changes to the regulatory environment for neuroscience treatments

Last Updated: Feb. 28, 2023 at 8:src4 p.m. ET

First Published: Feb. 28, 2023 at 5:35 p.m. ET

By

Jaimy Lee

Reata’s Skyclarys is a treatment for Friedreich’s ataxia, a rare inherited disease that causes damage to the nervous system

Getty Images/iStockphoto

Referenced Symbols

RETA

+src.04%

BIIB

+0.25%

4523

-0.45%

SPX

-0.30%

The U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc.’s treatment for Friedreich’s ataxia, a rare inherited disease that causes damage to the nervous system.

Reata’s RETA stock jumped more than src50% in after-hours trading, after being halted in advance of the FDA’s decision.

The drug, omaveloxolone, is now…

Read More